| scholarly article | Q13442814 |
| P50 | author | Gérard Waeber | Q29839423 |
| Christian Widmann | Q30505317 | ||
| Amar Abderrahmani | Q56810518 | ||
| P2093 | author name string | Romano Regazzi | |
| Bernard Thorens | |||
| Marion Cornu | |||
| Dimitri Favre | |||
| Jiang-Yan Yang | |||
| Guy Niederhauser | |||
| Mourad Ferdaoussi | |||
| Saida Abdelli | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1205-1215 | |
| P577 | publication date | 2008-02-05 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway | |
| P478 | volume | 57 |
| Q35643633 | A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent. |
| Q33850372 | Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function. |
| Q35055522 | Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass |
| Q35858008 | An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers |
| Q41128390 | Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke |
| Q34436650 | CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse β-cells |
| Q35899499 | CRFR1 activation protects against cytokine-induced β-cell death |
| Q91690121 | Clathrin-mediated Endocytosis of Alpha-1 Antitrypsin is Essential for its Protective Function in Islet Cell Survival |
| Q37725838 | Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells |
| Q35074567 | Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger |
| Q37396014 | Cyclophosphamide Induces an Early Wave of Acrolein-Independent Apoptosis in the Urothelium |
| Q37615190 | Decompensation of β-cells in diabetes: when pancreatic β-cells are on ICE(R). |
| Q37428593 | Development of insulin-producing cells from primitive biologic precursors |
| Q37206067 | Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study |
| Q39357027 | Effect of PANDER in βTC6-cell lipoapoptosis and the protective role of exendin-4 |
| Q52741508 | Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice |
| Q34405101 | Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation |
| Q28554206 | Endoplasmic Reticulum Stress Links Oxidative Stress to Impaired Pancreatic Beta-Cell Function Caused by Human Oxidized LDL |
| Q36719105 | Evidence for tuning adipocytes ICER levels for obesity care |
| Q90178371 | Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas |
| Q37253148 | Exendin-4 Promotes Survival of Mouse Pancreatic β-Cell Line in Lipotoxic Conditions, through the Extracellular Signal-Related Kinase 1/2 Pathway |
| Q39183486 | Exendin-4 Protects Hypoxic Islets From Oxidative Stress and Improves Islet Transplantation Outcome |
| Q34240080 | Exendin-4 Protects MIN6 Cells from t-BHP-Induced Apoptosis via IRE1-JNK-Caspase-3 Signaling |
| Q39292995 | Exendin-4 Protects Murine Pancreatic β-Cells from Free Fatty Acid-Induced Apoptosis Through PI-3K Signaling |
| Q52150032 | Exendin-4 attenuates brain death-induced liver damage in the rat. |
| Q39436443 | Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis |
| Q33927198 | Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects |
| Q35563969 | Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. |
| Q87872813 | Exendin-4 inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis |
| Q36109697 | Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. |
| Q35943572 | Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress |
| Q34682099 | Exendin-4 protects murine MIN6 pancreatic β-cells from interleukin-1β-induced apoptosis via the NF-κB pathway |
| Q39648782 | Exendin-4 protects murine pancreatic β-cells from dexamethasone-induced apoptosis through PKA and PI-3K signaling |
| Q39101720 | Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway |
| Q42255019 | Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins |
| Q28571413 | GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim |
| Q37805600 | Gastrointestinal hormones and the regulation of β-cell mass |
| Q64056345 | Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK/STAT3 signaling pathway |
| Q41692104 | Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1β-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma β cells |
| Q43136823 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure |
| Q47110705 | Inhibition of Vascular c-Jun N-Terminal Kinase 2 Improves Obesity-Induced Endothelial Dysfunction After Roux-en-Y Gastric Bypass. |
| Q36305288 | Islet Brain 1 Protects Insulin Producing Cells against Lipotoxicity |
| Q33852246 | JNK3 is required for the cytoprotective effect of exendin 4 |
| Q92612721 | Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes |
| Q47195081 | Loss-of-function mutations in ADCY3 cause monogenic severe obesity |
| Q52672848 | Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? |
| Q47424341 | Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness |
| Q38190197 | Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies |
| Q42171159 | Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes |
| Q38113095 | Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach |
| Q61942819 | Physiopathologie du diabète |
| Q64113046 | Poor short-term glycemic control in patients with type 2 diabetes impairs the intestinal mucosal barrier: a prospective, single-center, observational study |
| Q53207032 | Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice |
| Q33924202 | Regulation of CCAAT/enhancer-binding protein homologous protein (CHOP) expression by interleukin-1 beta in pancreatic beta cells |
| Q37603286 | Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes |
| Q35145993 | Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets |
| Q26995308 | Role of microRNAs in islet beta-cell compensation and failure during diabetes |
| Q36946301 | Shikonin Attenuates Concanavalin A-Induced Acute Liver Injury in Mice via Inhibition of the JNK Pathway |
| Q38584502 | Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes |
| Q38214020 | Targeting inflammation in the treatment of type 2 diabetes: time to start |
| Q34956310 | The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate. |
| Q83074871 | The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q28077026 | Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists |
| Q26824702 | Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales |
| Q38692970 | Use of additives, scaffolds and extracellular matrix components for improvement of human pancreatic islet outcomes in vitro: A systematic review |
Search more.